Tamil Nadu has received two consignments of Covifor, a generic version of the experimental COVID-19 drug remdesivir, from Hyderabad-based Hetero, and has dispatched them to all districts for treatment of critical COVID-19 patients.
Umanath, managing director, Tamil Nadu Medical Services Corporation, said, “We have ordered a consignment of 42,500 vials of the medicine, the largest number ordered by any State till date.”
He added: “We have dispatched the first consignment and it has already reached all government hospitals, medical college hospitals and district headquarters hospitals in districts where there are no medical colleges. In fact, we got some quantity for compassionate use last week itself.”
Homegrown pharma major Hetero has started delivering the generic version of antiviral drug Remdesivir to states across the country for the treatment of Covid-19 patients. Sold under the brand name Covifor, the drug has been priced at Rs 5,400 per vial and will be available at hospitals to treat the coronavirus infection.
On Sunday, pharma company Hetero had announced it has received both manufacturing and marketing approval for the investigational antiviral drug Remdesivir, from the Drug Controller General of India (DCGI) to treat Covid-19 patients.
Hetero said a 100-milligram vial of the drug will cost Rs 5,400. The recommended dose for adults and pediatric patients is 200 mg on Day 1 followed by once daily maintenance doses of 100 mg for five days.
The company has set a target to produce one lakh vials of the drug in three-four weeks. Currently, the drug is being manufactured at the company’s formulation facility in Hyderabad.